Logo image
Immunostimulation in the era of the metagenome
Journal article   Peer reviewed

Immunostimulation in the era of the metagenome

A.D. Proal, P.J. Albert, G.P. Blaney, I.A. Lindseth, C. Benediktsson and T.G. Marshall
Cellular and Molecular Immunology, Vol.8(3), pp.213-225
2011
url
Link to Published Version *Subscription may be requiredView

Abstract

Microbes are increasingly being implicated in autoimmune disease. This calls for a re-evaluation of how these chronic inflammatory illnesses are routinely treated. The standard of care for autoimmune disease remains the use of medications that slow the immune response, while treatments aimed at eradicating microbes seek the exact opposite-stimulation of the innate immune response. Immunostimulation is complicated by a cascade of sequelae, including exacerbated inflammation, which occurs in response to microbial death. Over the past 8 years, we have collaborated with American and international clinical professionals to research a model-based treatment for inflammatory disease. This intervention, designed to stimulate the innate immune response, has required a reevaluation of disease progression and amelioration. Paramount is the inherent conflict between palliation and microbicidal efficacy. Increased microbicidal activity was experienced as immunopathology-a temporary worsening of symptoms. Further studies are needed, but they will require careful planning to manage this immunopathology.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.80 Bone Diseases
1.80.279 Vitamin D
Web Of Science research areas
Immunology
ESI research areas
Immunology
Logo image